Enrollment into Akebia Therapeutics' (AKBA) AKB-6548 Phase 2b Completes
Tweet Send to a Friend
Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced it has completed enrollment in its ongoing 200-patient Phase 2b study of AKB-6548 for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
